SIGA to Host Business Update Call on November 7 Following Release of Third-Quarter 2024 Financial Results
SIGA Technologies (NASDAQ: SIGA) announced it will host a webcast and conference call to provide a business update on November 7, 2024, at 4:30 P.M. ET. CEO Diem Nguyen and CFO Daniel Luckshire will participate in the call. The webcast will be available on the company's website, with dial-in options for domestic (1-800-717-1738) and international callers (1-646-307-1865). A two-week replay will be available via phone and the company website.
SIGA Technologies (NASDAQ: SIGA) ha annunciato che ospiterà un webcast e una conferenza telefonica per fornire un aggiornamento aziendale il 7 novembre 2024, alle 16:30 ET. Il CEO Diem Nguyen e il CFO Daniel Luckshire parteciperanno alla telefonata. Il webcast sarà disponibile sul sito web dell'azienda, con opzioni di accesso per i chiamanti nazionali (1-800-717-1738) e internazionali (1-646-307-1865). Una replica di due settimane sarà disponibile tramite telefono e sul sito web dell'azienda.
SIGA Technologies (NASDAQ: SIGA) anunció que llevará a cabo un webcast y una conferencia telefónica para proporcionar una actualización empresarial el 7 de noviembre de 2024, a las 4:30 P.M. ET. El CEO Diem Nguyen y el CFO Daniel Luckshire participarán en la llamada. El webcast estará disponible en el sitio web de la empresa, con opciones de acceso para los llamantes nacionales (1-800-717-1738) e internacionales (1-646-307-1865). Una repetición de dos semanas estará disponible a través del teléfono y en el sitio web de la empresa.
SIGA Technologies (NASDAQ: SIGA)는 2024년 11월 7일 오후 4시 30분 ET에 비즈니스 업데이트를 제공하기 위해 웹캐스트 및 컨퍼런스 콜을 개최할 것이라고 발표했습니다. CEO Diem Nguyen과 CFO Daniel Luckshire가 통화에 참여할 예정입니다. 웹캐스트는 회사의 웹사이트에서 이용 가능하며, 국내(1-800-717-1738) 및 국제 전화(1-646-307-1865)를 위한 다이얼인 옵션이 제공됩니다. 2주 간의 재생이 전화와 회사 웹사이트를 통해 제공됩니다.
SIGA Technologies (NASDAQ: SIGA) a annoncé qu'elle organisera un webcast et une conférence téléphonique afin de fournir une mise à jour sur les activités le 7 novembre 2024 à 16h30 ET. Le CEO Diem Nguyen et le CFO Daniel Luckshire participeront à l'appel. Le webcast sera disponible sur le site de l'entreprise, avec des options de connexion pour les appelants nationaux (1-800-717-1738) et internationaux (1-646-307-1865). Un replay de deux semaines sera disponible par téléphone et sur le site de l'entreprise.
SIGA Technologies (NASDAQ: SIGA) gab bekannt, dass am 7. November 2024 um 16:30 Uhr ET ein Webcast und eine Telefonkonferenz zur Bereitstellung eines Unternehmensupdates stattfindet. CEO Diem Nguyen und CFO Daniel Luckshire werden an dem Anruf teilnehmen. Der Webcast wird auf der Unternehmenswebsite verfügbar sein, mit Einwahlmöglichkeiten für Anrufer aus dem Inland (1-800-717-1738) und dem Ausland (1-646-307-1865). Eine zweiwöchige Wiederholung wird telefonisch und über die Unternehmenswebsite verfügbar sein.
- None.
- None.
NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, November 7, 2024. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.
A live webcast of the call will also be available on the Company's website at http://www.siga.com in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time.
Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers.
A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 1146096. The archived webcast will be available in the Investor Relations section of the Company's website.
About SIGA
SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world’s most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. Our flagship product, TPOXX® (tecovirimat), is an antiviral medicine approved in the U.S. and Canada for the treatment of smallpox and authorized in Europe and the UK for the treatment of smallpox, mpox (monkeypox), cowpox, and vaccinia complications. For more information about SIGA, visit http://www.siga.com.
| Contacts: Suzanne Harnett sharnett@siga.com and | |
| Investors | Media |
| Jennifer Drew-Bear, Edison Group Jdrew-bear@edisongroup.com | Holly Stevens, Berry & Company hstevens@berrypr.com |
FAQ
When will SIGA Technologies (SIGA) release its Q3 2024 financial results?
How can investors access SIGA's Q3 2024 earnings call?
How long will SIGA's Q3 2024 earnings call replay be available?
